Clinical endpoint data collection, predictive analytics, and real world evidence – draw on our science, technological, global experience and credibility, learned over 15k trials, to power your clinical development with certainty, quality and speed


Patients Enrolled


Sites Supported


Drug Approvals


Trials Managed

a better way to manage your clinical development

Meet goals and achieve higher quality data, reduced costs, and shortened study timelines with support from ERT.

a better way to manage your trials

Meet clinical development goals and achieve higher quality data, reduced costs, and shortened study timelines with support from ERT.


moving ahead requires a sure path forward

Every detail matters. We spot risks before they become problems and help you avoid costly delays through our latest solution Trial Oversight.


We deliver the flexibility and adaptability you need to overcome challenges for faster speed to market. Here’s how:

230k investigative sites supported
Every trial runs into unexpected challenges. With more than 15,000 trials under our belt, we’ve seen them before and have the expertise to put your trial back on course with our predictive analytics.
25 ready-to-launch analytics tools
We protect  your trial before there’s ever an issue, ensuring its success through near real-time access to study, program and enterprise-level performance.



ERT Leader Recognized by PharmaVoice for Delivering Innovation in Clinical Trial Imaging

Timothy Kulbago, Vice President, Imaging has been named one of the 100 most inspiring individuals in the life-sciences industry by PharmaVoice.

ERT Recognized for Innovation in Health Technology: Pittsburgh Technology Council names ERT to Tech 50

ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced it has been named one of the 50 most successful and innovative technology companies of the Pittsburgh region by the Pittsburgh Technology Council.

Patient-Reported Outcome (PRO) Data in Oncology Trials – Part 1: Regulations

In this first of a 2-part series on the importance of PRO data in oncology drug development, we review the latest regulatory guidances recommending the use of PROs in oncology trials.